Mass Spectrometry of Glycoproteins pp 307-322

Part of the Methods in Molecular Biology book series (MIMB, volume 951)

Elucidation of N-Glycosites Within Human Plasma Glycoproteins for Cancer Biomarker Discovery

  • Penelope Drake
  • Birgit Schilling
  • Brad Gibson
  • Susan Fisher
Protocol

Abstract

Glycans are an important class of post-translational modifications that decorate a wide array of protein substrates. These cell-type specific molecules, which are modulated during developmental and disease processes, are attractive biomarker candidates as biology regarding altered glycosylation can be used to guide the experimental design. The mass spectrometry (MS)-based workflow described here incorporates chromatography on affinity matrices formed from lectins, proteins that bind specific glycan motifs. The goal was to design a relatively simple method for the rapid analysis of small plasma volumes (e.g., clinical specimens). As increases in sialylation and fucosylation are prominent among cancer-associated modifications, we focused on Sambucus nigra agglutinin and AAL, which bind sialic acid- and fucose-containing structures, respectively. Positive controls (fucosylated and sialylated human lactoferrin glycopeptides), and negative controls (high-mannose glycopeptides from Saccharomyces cerevisiae invertase) were used to monitor the specificity of lectin capture and optimize the workflow. Multiple Affinity Removal System 14-depleted, trypsin-digested human plasma from healthy donors served as the target analyte. Samples were loaded onto the lectin columns and separated by high performance liquid chromatography (HPLC) into flow through and bound fractions, which were treated with PNGase F, an amidase that removes N-linked glycans and marks the underlying asparagine glycosite by a +1 Da mass shift. The deglycosylated peptide fractions were interrogated by HPLC ESI-MS/MS on a quadrupole time-of-flight mass spectrometer. The method allowed identification of 122 human plasma glycoproteins containing 247 unique glycosites. Notably, glycoproteins that circulate at ng/mL levels (e.g., cadherin-5 at 0.3–4.9 ng/mL, and neutrophil gelatinase-associated lipocalin which is present at ∼2.5 ng/mL) were routinely observed, suggesting that this method enables the detection of low-abundance cancer-specific glycoproteins.

Key words

Lectin chromatography Glycopeptide Plasma Cancer Biomarker discovery Mass spectrometry 

References

  1. 1.
    Meezan E, Wu HC, Black PH, Robbins PW (1969) Comparative studies on the carbohydrate-containing membrane components of normal and virus-transformed mouse fibroblasts. II. Separation of glycoproteins and glycopeptides by sephadex chromatography. Biochemistry 8:2518–2524CrossRefPubMedGoogle Scholar
  2. 2.
    Barkauskas DA, An HJ, Kronewitter SR, de Leoz ML, Chew HK, de Vere White RW, Leiserowitz GS, Miyamoto S, Lebrilla CB, Rocke DM (2009) Detecting glycan cancer biomarkers in serum samples using MALDI FT-ICR mass spectrometry data. Bioinformatics 25:251–257CrossRefPubMedGoogle Scholar
  3. 3.
    Goldberg D, Bern M, Parry S, Sutton-Smith M, Panico M, Morris HR, Dell A (2007) Automated N-glycopeptide identification using a combination of single- and tandem-MS. J Proteome Res 6:3995–4005CrossRefPubMedGoogle Scholar
  4. 4.
    Harvey DJ (2005) Structural determination of N-linked glycans by matrix-assisted laser desorption/ionization and electrospray ionization mass spectrometry. Proteomics 5:1774–1786CrossRefPubMedGoogle Scholar
  5. 5.
    North SJ, Hitchen PG, Haslam SM, Dell A (2009) Mass spectrometry in the analysis of N-linked and O-linked glycans. Curr Opin Struct Biol 19:498–506CrossRefPubMedPubMedCentralGoogle Scholar
  6. 6.
    Royle L, Campbell MP, Radcliffe CM, White DM, Harvey DJ, Abrahams JL, Kim YG, Henry GW, Shadick NA, Weinblatt ME, Lee DM, Rudd PM, Dwek RA (2008) HPLC-based analysis of serum N-glycans on a 96-well plate platform with dedicated database software. Anal Biochem 376:1–12CrossRefPubMedGoogle Scholar
  7. 7.
    Wong SC, Chan CM, Ma BB, Lam MY, Choi GC, Au TC, Chan AS, Chan AT (2009) Advanced proteomic technologies for cancer biomarker discovery. Expert Rev Proteomics 6:123–134CrossRefPubMedGoogle Scholar
  8. 8.
    Barrabes S, Pages-Pons L, Radcliffe CM, Tabares G, Fort E, Royle L, Harvey DJ, Moenner M, Dwek RA, Rudd PM, De Llorens R, Peracaula R (2007) Glycosylation of serum ribonuclease 1 indicates a major endothelial origin and reveals an increase in core fucosylation in pancreatic cancer. Glycobiology 17:388–400CrossRefPubMedGoogle Scholar
  9. 9.
    Kuzmanov U, Jiang N, Smith CR, Soosaipillai A, Diamandis EP (2009) Differential N-glycosylation of kallikrein 6 derived from ovarian cancer cells or the central nervous system. Mol Cell Proteomics 8:791–798CrossRefPubMedPubMedCentralGoogle Scholar
  10. 10.
    Meany DL, Zhang Z, Sokoll LJ, Zhang H, Chan DW (2009) Glycoproteomics for prostate cancer detection: changes in serum PSA glycosylation patterns. J Proteome Res 8:613–619CrossRefPubMedPubMedCentralGoogle Scholar
  11. 11.
    Misonou Y, Shida K, Korekane H, Seki Y, Noura S, Ohue M, Miyamoto Y (2009) Comprehensive clinico-glycomic study of 16 colorectal cancer specimens: elucidation of aberrant glycosylation and its mechanistic causes in colorectal cancer cells. J Proteome Res 8:2990–3005CrossRefPubMedGoogle Scholar
  12. 12.
    Mizuochi T, Nishimura R, Derappe C, Taniguchi T, Hamamoto T, Mochizuki M, Kobata A (1983) Structures of the asparagine-linked sugar chains of human chorionic gonadotropin produced in choriocarcinoma. Appearance of triantennary sugar chains and unique biantennary sugar chains. J Biol Chem 258:14126–14129PubMedGoogle Scholar
  13. 13.
    Ohyama C, Hosono M, Nitta K, Oh-eda M, Yoshikawa K, Habuchi T, Arai Y, Fukuda M (2004) Carbohydrate structure and differential binding of prostate specific antigen to Maackia amurensis lectin between prostate cancer and benign prostate hypertrophy. Glycobiology 14:671–679CrossRefPubMedGoogle Scholar
  14. 14.
    Taylor AD, Hancock WS, Hincapie M, Taniguchi N, Hanash SM (2009) Towards an integrated proteomic and glycomic approach to finding cancer biomarkers. Genome Med 1:57CrossRefPubMedPubMedCentralGoogle Scholar
  15. 15.
    Cho W, Jung K, Regnier FE (2008) Use of glycan targeting antibodies to identify cancer-associated glycoproteins in plasma of breast cancer patients. Anal Chem 80:5286–5292CrossRefPubMedGoogle Scholar
  16. 16.
    Heo SH, Lee SJ, Ryoo HM, Park JY, Cho JY (2007) Identification of putative serum glycoprotein biomarkers for human lung adenocarcinoma by multilectin affinity chromatography and LC-MS/MS. Proteomics 7:4292–4302CrossRefPubMedGoogle Scholar
  17. 17.
    Jung K, Cho W, Regnier FE (2009) Glycoproteomics of plasma based on narrow selectivity lectin affinity chromatography. J Proteome Res 8:643–650CrossRefPubMedGoogle Scholar
  18. 18.
    Kaji H, Saito H, Yamauchi Y, Shinkawa T, Taoka M, Hirabayashi J, Kasai K, Takahashi N, Isobe T (2003) Lectin affinity capture, isotope-coded tagging and mass spectrometry to identify N-linked glycoproteins. Nat Biotechnol 21:667–672CrossRefPubMedGoogle Scholar
  19. 19.
    Plavina T, Wakshull E, Hancock WS, Hincapie M (2007) Combination of abundant protein depletion and multi-lectin affinity chromatography (M-LAC) for plasma protein biomarker discovery. J Proteome Res 6:662–671CrossRefPubMedGoogle Scholar
  20. 20.
    Zhang H, Li XJ, Martin DB, Aebersold R (2003) Identification and quantification of N-linked glycoproteins using hydrazide chemistry, stable isotope labeling and mass spectrometry. Nat Biotechnol 21:660–666CrossRefPubMedGoogle Scholar
  21. 21.
    Drake PM, Schilling B, Niles RK, Braten M, Johansen E, Liu H, Lerch M, Sorensen DJ, Li B, Allen S, Hall SC, Witkowska HE, Regnier FE, Gibson BW, Fisher SJ (2011) A lectin affinity workflow targeting glycosite-specific, cancer-related carbohydrate structures in trypsin-digested human plasma. Anal Biochem 408:71–85CrossRefPubMedGoogle Scholar
  22. 22.
    Keshishian H, Addona T, Burgess M, Kuhn E, Carr SA (2007) Quantitative, multiplexed assays for low abundance proteins in plasma by targeted mass spectrometry and stable isotope dilution. Mol Cell Proteomics 6:2212–2229CrossRefPubMedPubMedCentralGoogle Scholar
  23. 23.
    Soeki T, Tamura Y, Shinohara H, Sakabe K, Onose Y, Fukuda N (2004) Elevated concentration of soluble vascular endothelial cadherin is associated with coronary atherosclerosis. Circ J 68:1–5CrossRefPubMedGoogle Scholar
  24. 24.
    Krokhin OV, Antonovici M, Ens W, Wilkins JA, Standing KG (2006) Deamidation of -Asn-Gly- sequences during sample preparation for proteomics: consequences for MALDI and HPLC-MALDI analysis. Anal Chem 78:6645–6650CrossRefPubMedGoogle Scholar
  25. 25.
    Matsumoto A, Yoshima H, Takasaki S, Kobata A (1982) Structural study of the sugar chains of human lactoferrin: finding of four novel complex-type asparagine-linked sugar chains. J Biochem 91:143–155PubMedGoogle Scholar
  26. 26.
    Spik G, Strecker G, Fournet B, Bouquelet S, Montreuil J, Dorland L, van Halbeek H, Vliegenthart JF (1982) Primary structure of the glycans from human lactotransferrin. Eur J Biochem 121:413–419CrossRefPubMedGoogle Scholar
  27. 27.
    Trimble RB, Atkinson PH (1986) Structure of yeast external invertase Man8-14GlcNAc processing intermediates by 500-megahertz 1H NMR spectroscopy. J Biol Chem 261:9815–9824PubMedGoogle Scholar

Copyright information

© Springer Science+Business Media, LLC 2013

Authors and Affiliations

  • Penelope Drake
    • 1
  • Birgit Schilling
    • 2
  • Brad Gibson
    • 1
  • Susan Fisher
    • 1
  1. 1.Department of Obstetrics, Gynecology and Reproductive SciencesUniversity of CaliforniaSan FranciscoUSA
  2. 2.Buck Institute for Age ResearchNovatoUSA

Personalised recommendations